News for Editas Medicine, Inc. (EDIT)

Editas Medicine struggles with underwhelming data and lacks major partnerships. Find out why EDIT stock faces significant risks with little catalyst until 2026.

**media[582597]**

Erick J. Lucera to Step Down as CFO to pursue another opportunity Senior Vice President of Finance Amy Parison Appointed CFO CAMBRIDGE, Mass., March 20, 2025

**media[572477,572478]**

**media[572461,572462]**

Editas Medicine, Inc. (NASDAQ:EDIT) Barclays 27th Annual Global Healthcare Conference March 11, 2025 9:00 AM ETCompany ParticipantsGilmore O’Neill -...

Editas Medicine, Inc. (NASDAQ:EDIT) Leerink Partners Global Healthcare Conference March 10, 2025 9:20 AM ETCompany ParticipantsGilmore O’Neill - President...

Editas (EDIT) delivered earnings and revenue surprises of -41.03% and 19.18%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Editas Medicine press release (NASDAQ:EDIT): Q4 GAAP EPS of -$0.55 misses by $0.20.Revenue of $30.6M (-49.0% Y/Y) misses by $6.57M.Cash, cash equivalents,...

Editas Medicine, Inc. (NASDAQ:EDIT) TD Cowen 45th Annual Health Care Conference March 3, 2025 2:30 PM ETCompany ParticipantsGilmore O'Neill - Chief...

CAMBRIDGE, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. ( EDIT), a pioneering gene editing company focused on developing transformative medi

China-based WORK Medical Technology Group LTD (WOK) is up over 94 percent in Thursday's pre-market trading. The following are some of the other stocks making big moves in Thursday's pre-market trading.

Editas Medicine, Inc. (NASDAQ:EDIT) 43rd Annual JPMorgan Healthcare Conference Call January 15, 2025 2:15 PM ETCompany ParticipantsGilmore O'Neill -...

Editas Medicine stock hits 52-week low at $1.16 amid steep decline

CAMBRIDGE, Mass., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. ( EDIT), a leading gene editing company, today announced that the Company's Presiden

Editas Medicine stock plunges to 52-week low of $1.27

Brokerages downgrade gene editing company Editas to 'hold', shares slump 23%

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please ...

Andy/iStock via Getty Images Editas Medicine (NASDAQ:EDIT) plans to slash around 180 jobs, or approximately 65% of its workforce, over the next six months...